This is the authors' abstract. We don't add key points for this paper.
Mitochondrial dysfunction, persistent inflammation, maladaptive tubular repair and tubulointerstitial fibrosis are major causative factors that contribute to the onset and progression of acute kidney disease (AKD) and chronic kidney disease (CKD). Here, we investigate the therapeutic potential of MARY1, a novel, potent, and selective 5-hydroxytryptamine 2B (5-HT 2B ) receptor antagonist, on multiple key hallmarks known to drive the AKI-to-AKD transition. A mouse model of bilateral ischemia/reperfusion-induced renal injury was used to determine the therapeutic potential of MARY1 in vivo. Primary rabbit renal proximal tubule cells (RPTCs) were used to evaluate the cellular signaling effects of MARY1. Daily administration of MARY1 for 30 days (0.3 mg/kg, i.p.) post-injury restored renal function and mitochondrial biogenesis/dynamics. MARY1 also suppressed epithelial–mesenchymal and endothelial–mesenchymal transition (VE-cadherin, vimentin, FSP1, MMP-9), and reduced renal fibrosis (TGF-β, COL1A1, α-SMA). Furthermore, MARY1 attenuated inflammation as evidenced by downregulated NF-κB signaling and proinflammatory chemokine CXCL10, and augmented anti-inflammatory cytokines IL-9, IL-10, and IL-13. Importantly, MARY1 reduced p53 and p21 expression, indicating alleviated cell-cycle arrest. MARY1 also upregulated genes associated with successful proximal tubule cell repair (ACSM2A), while suppressing genes linked to failed repair (VCAM1 and PDGFRβ). These findings identify MARY1 as a novel, potent and selective 5-HT 2B receptor antagonist that restores mitochondrial homeostasis, promotes adaptive tubular repair, and prevents renal fibrosis following renal injury, thereby alleviating early AKD-to-AKD transition. This work highlights 5-HT 2B receptor antagonism and MARY1 as a promising therapeutic strategy to improve renal function and early recovery after ischemic injury.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Raj et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: